Wealthcare Advisory Partners LLC Buys 436 Shares of Illumina, Inc. (NASDAQ:ILMN)

Wealthcare Advisory Partners LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 11.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,214 shares of the life sciences company’s stock after purchasing an additional 436 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Illumina were worth $563,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC bought a new stake in shares of Illumina in the 2nd quarter worth about $313,000. Pacer Advisors Inc. boosted its position in Illumina by 71.9% in the second quarter. Pacer Advisors Inc. now owns 31,762 shares of the life sciences company’s stock valued at $3,315,000 after buying an additional 13,290 shares in the last quarter. Sei Investments Co. grew its stake in Illumina by 37.3% during the second quarter. Sei Investments Co. now owns 97,681 shares of the life sciences company’s stock worth $10,196,000 after buying an additional 26,538 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Illumina by 97.1% during the second quarter. Thrivent Financial for Lutherans now owns 60,298 shares of the life sciences company’s stock worth $6,294,000 after buying an additional 29,709 shares in the last quarter. Finally, Westwood Holdings Group Inc. bought a new position in shares of Illumina in the second quarter valued at approximately $1,656,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Barclays boosted their price objective on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. TD Cowen upped their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Stock Performance

Shares of ILMN opened at $136.67 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a market capitalization of $21.68 billion, a price-to-earnings ratio of -13.72 and a beta of 1.11. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The stock’s 50-day simple moving average is $139.60 and its 200 day simple moving average is $133.77.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.33 EPS. Research analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.